CN113454220B - 针对人细胞间粘附分子1(icam-1)的反义药物 - Google Patents

针对人细胞间粘附分子1(icam-1)的反义药物 Download PDF

Info

Publication number
CN113454220B
CN113454220B CN201980089644.3A CN201980089644A CN113454220B CN 113454220 B CN113454220 B CN 113454220B CN 201980089644 A CN201980089644 A CN 201980089644A CN 113454220 B CN113454220 B CN 113454220B
Authority
CN
China
Prior art keywords
icam
oligonucleotides
seq
antisense oligonucleotide
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980089644.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN113454220A (zh
Inventor
格奥尔格·斯扎基尔
勒泽尔·克雷奇默-卡其米法尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitat zu Lubeck
Original Assignee
Universitat zu Lubeck
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat zu Lubeck filed Critical Universitat zu Lubeck
Publication of CN113454220A publication Critical patent/CN113454220A/zh
Application granted granted Critical
Publication of CN113454220B publication Critical patent/CN113454220B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201980089644.3A 2019-01-25 2019-12-17 针对人细胞间粘附分子1(icam-1)的反义药物 Active CN113454220B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19153666 2019-01-25
EP19153666.3 2019-01-25
PCT/EP2019/085539 WO2020151881A1 (en) 2019-01-25 2019-12-17 Antisense drug against the human intercellular adhesion molecule 1 (icam-1)

Publications (2)

Publication Number Publication Date
CN113454220A CN113454220A (zh) 2021-09-28
CN113454220B true CN113454220B (zh) 2024-08-23

Family

ID=65234475

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980089644.3A Active CN113454220B (zh) 2019-01-25 2019-12-17 针对人细胞间粘附分子1(icam-1)的反义药物

Country Status (6)

Country Link
US (1) US12480128B2 (https=)
EP (1) EP3914710A1 (https=)
JP (1) JP7307505B2 (https=)
KR (1) KR102808320B1 (https=)
CN (1) CN113454220B (https=)
WO (1) WO2020151881A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114525244A (zh) * 2022-02-15 2022-05-24 中南大学 一种牙周牙髓联合病变组织中间充质干细胞的焦亡产物在疾病发生发展中的机制研究方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018907A2 (de) * 1998-09-25 2000-04-06 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Antisense-sequenzen für die hemmung der expression des adhäsionsmoleküls icam-1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002256359A1 (en) * 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
US7919472B2 (en) * 2004-09-17 2011-04-05 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
US11293064B2 (en) * 2013-05-02 2022-04-05 Thomas Jefferson University Human miRNAs for use in diagnosis, prognosis, and therapy of human conditions and diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018907A2 (de) * 1998-09-25 2000-04-06 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Antisense-sequenzen für die hemmung der expression des adhäsionsmoleküls icam-1

Also Published As

Publication number Publication date
KR20210120034A (ko) 2021-10-06
US20220106601A1 (en) 2022-04-07
WO2020151881A1 (en) 2020-07-30
EP3914710A1 (en) 2021-12-01
JP2022524913A (ja) 2022-05-11
KR102808320B1 (ko) 2025-05-15
JP7307505B2 (ja) 2023-07-12
US12480128B2 (en) 2025-11-25
CN113454220A (zh) 2021-09-28

Similar Documents

Publication Publication Date Title
EP4137161A1 (en) Method and drug for treating hurler syndrome
EP2895200B1 (en) Multimeric oligonucleotide compounds
JP4643906B2 (ja) 遺伝子発現の標的化阻害のための合成二本鎖オリゴヌクレオチド
EP2756080B1 (en) Multimeric oligonucleotide compounds
JP2022078069A (ja) 二本鎖ＲＮＡによるα－１アンチトリプシンの特異的阻害のための方法及び組成物
US7709456B2 (en) Modulation of gene expression by oligomers targeted to chromosomal DNA
Hirota et al. Genome-wide gene expression profiles of clear cell renal cell carcinoma: identification of molecular targets for treatment of renal cell carcinoma
EP2077326A1 (en) Novel nucleic acid
EP2906697A1 (en) Methods for monitoring c9orf72 expression
EP2123752A2 (en) Novel nucleic acid
EP2298359A1 (en) Nucleic acid capable of controlling degranulation of mast cell
JP2025148338A (ja) Ｒｎａ治療薬及びその使用方法
CA3193112A1 (en) Grna targeting ctgf gene and use thereof
CN113454220B (zh) 针对人细胞间粘附分子1(icam-1)的反义药物
TW201119681A (en) Compositions and methods for inhibiting expression of KIF10 genes
US20220298512A1 (en) Sirna sequences targeting the expression of human genes jak1 or jak3 for a therapeutic use
EP1668144A2 (en) Nucleotide sequences promoting the trans-membrane transport of nucleic acids
JP2026510408A (ja) 神経障害の処置のためのアンチセンスオリゴヌクレオチド
EP4711455A1 (en) Small artificial rna (smartrna) oligonucleotide for modulating protein expression
EP4537833A1 (en) Pharmaceutical composition for fibrosis treatment
WO2012135152A1 (en) Compositions for inhibiting gene expression and uses thereof
WO2024251244A1 (zh) 多核苷酸、药物组合物及其用途
WO2026064592A1 (en) Oligonucleotide-mediated knockdown of slc6a19
WO2026026534A1 (zh) 抑制ANGTPL3的siRNA及其修饰物与应用
CN121846123A (zh) 多核苷酸序列的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant